Combining Animal Models with Advanced Neuroscience, Machine Learning, and Drug Delivery Technologies to Advance KNX100 for the Treatment of Agitation in Dementia & Substance Use Disorders
Time: 12:15 pm
day: Day One Track A AM
Details:
- KNX100 is a novel, clinical-stage treatment being developed for the treatment of agitation in dementia and substance use disorders
- Using time-locked, high temporal resolution neural and video recordings to enhance confidence in the disease relevance of preclinical behavioural and biological readouts
- Chronic steady-state dosing in animal models to improve the precision and predictive utility of preclinical PKPD profiles guiding clinical studies
- Harmonization of preclinical and clinical methods to facilitate translation of neural biomarkers
